Mucoprotective effect of a galactomannan- and hyaluronic-based medical device in a reconstructed human esophageal epithelium. in Minerva gastroenterology / Minerva Gastroenterol (Torino). 2022 Dec;68(4):387-392. doi: 10.23736/S2724-5985.21.03120-X. Epub 20
2022
AOU Città della Salute di Torino
Tipo pubblicazione
Journal Article
Autori/Collaboratori (4)Vedi tutti...
Pellicano R
Unit of Gastroenterology, San Giovanni Antica Sede (SGAS) Hospital, Molinette Hospital, Città della Salute e della Scienza, Turin, Italy - rinaldo_pellican@hotmail.com.
Gesualdo M
Unit of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy.
Fagoonee S
Institute of Biostructure and Bioimaging (CNR), Molecular Biotechnology Center, Turin, Italy.
et alii...
Abstract
BACKGROUND: Gastroesophageal reflux disease (GERD) is a common disorder characterized by troublesome symptoms (classically, heartburn and regurgitation). Repeated or prolonged exposure to gastric contents may cause irritation and inflammation of the esophageal mucosa. RefluG™ is a medical device conceived to form a physical barrier on contact with gastric contents, neutralize stomach acid excess, and elicit a mucoprotective effect. The aim of the current study was to investigate the mucoprotective potential of RefluG™ (IHS, Biofarma Group, Lissone, Italy) in a simulated reflux model. METHODS: A 3D reconstructed human esophageal epithelium was treated with RefluG™ or sodium alginate (reference sample) or saline solution (negative control) or acid solution (positive control) in a prevention or treatment approach. Histological protection, mucoprotective and barrier effects were evaluated. Preservation of epithelial permeability was determined by measuring the transepithelial electrical resistance (TEER) and the Lucifer yellow assay. Interleukin (IL)-6 levels were determined as indicator of the ability of RefluG™ to attenuate and/or prevent esophageal irritation. RESULTS: RefluG™ was found to better preserve tissue morphology while the epithelial membranes showed higher integrity, as revealed by TEER analysis, compared to the other samples. Luciferin passage was significantly reduced following RefluG™ treatment with respect to other treatment groups. Moreover, after acid insult, RefluG™ treatment significantly decreased IL-6 release into the culture media compared to the reference sample or positive control. CONCLUSIONS: These results provide experimental evidence on the efficacy of RefluG™ in preserving the integrity of the esophageal barrier and support data regarding the symptomatic relief observed in patients with GERD receiving RefluG™ as monotherapy.
Accesso banca dati bibliografica
Accedi alla scheda bibliografica del documento in PUBMED
PMID : 34930000
DOI : 10.23736/S2724-5985.21.03120-X
Keywords
Epithelium; Heartburn/complications; Esophageal Mucosa; Gastroesophageal Reflux/drug therapy/diagnosis/etiology; Humans;